EVAX logo

EVAXION A/S

EVAXNASDAQ
🏆 #4769 by market capUS Equity
$3.27▲ $0.06 (+1.87%)
Market closed · at close
🔔
Track EVAX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.9%
7d▲ 0.3%
14d▲ 3.5%
30d▲ 8.3%
ytd▼ 32.0%
1y▼ 13.3%
🏦Market Cap
$21M
Small Cap
📈Revenue Growth (YoY)
+125.1%
High Growth
📊Gross Margin
100.0%
High
💵FCF Margin
—
⚖️P/S Ratio
2.7x
Cheap
Otter Score
40
Weak

Trading Snapshot

Day Range
$3.24 – $3.29
52-Week Range
$2.77 – $12.15
Volume
$3.43B
Avg Volume
$4.48B
Shares Outstanding
6.3M
Next Earnings
Oct 26, 2026

Fundamentals Snapshot

Annual Revenue
$8M
Last Q Revenue
$2M
P/E Ratio
-0.5
P/S Ratio
2.7x
EPS (TTM)
$-20.75
Dividend Yield
0.00%
Dilution (1yr)
+497.3%

Why Investors Own EVAX

  • ✓High-growth profile — revenue up -0.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 44% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EVAX logo

EVAXION A/S

EVAX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$8M▲ +125.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −37.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▼ −48.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
6.4M▲ +497.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$16M▲ +$21M YoY
StockOtter · stockotter.space

About EVAXION A/S

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
40/100

Analyst Price Target

ⓘ
Average Target
$3.61
▲ +10.3% Upside
High Target$4.33
Low Target$3.19
Based on 34 analysts

Latest News & Updates

🚀
CNBC·2h ago

EVAXION A/S tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift EVAX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

EVAXION A/S announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.